PMID- 37578070
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 23
IP  - 8
DP  - 2023 Jul-Dec
TI  - The economics of biosimilars and challenges to biosimilar adoption in low- and 
      middle-income countries.
PG  - 653-657
LID - 10.1080/14712598.2023.2247972 [doi]
AB  - INTRODUCTION: Biologics have shown marked success over the past decades in 
      disease areas as cancer, immunology and diabetes. However, elevated costs of 
      innovative biologic medicines have led to an inequity in accessibility across the 
      world. While 85% of the world's population lives in low- and middle- income 
      countries (LMIC), 80% of the sales of monoclonal antibodies are attributed to 
      Western countries, highlighting the pronounced market imbalance. AREAS COVERED: 
      This perspective paper draws some analogies as well as differences between 
      biosimilars and generics, aims to address the unmet need for treatment with 
      biologics in LMICs by reviewing possible causes, economic and social, of low 
      access, displaying the disparity between LMICs and HIC, and suggets 
      countermeasures for this unmet medical need in LMICs. EXPERT OPINION: It is up to 
      all stakeholders to capitalize on the opportunity that biosimilars provide, 
      mostly by committing to transparent collaboration, to make biotherapeutics 
      accessible to all, regardless of region or country of residence.
FAU - Calamia, Matthias
AU  - Calamia M
AD  - Medicines, National Health Care Institute, Amsterdam, The Netherlands.
AD  - Matrix45, Tucson, AZ, USA.
FAU - Abraham, Ivo
AU  - Abraham I
AD  - Matrix45, Tucson, AZ, USA.
AD  - Center for Health Outcomes and PharmacoEconomic Research, R. Ken Coit College of 
      Pharmacy, University of Arizona, Tucson, AZ, USA.
LA  - eng
PT  - Journal Article
DEP - 20230818
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - *Biosimilar Pharmaceuticals/therapeutic use
MH  - Developing Countries
MH  - *Neoplasms
MH  - Antibodies, Monoclonal
OTO - NOTNLM
OT  - LMIC
OT  - LMICs
OT  - biologics
OT  - biosimilars
OT  - biotherapeutics
OT  - low- and middle-income countries
EDAT- 2023/08/14 12:43
MHDA- 2023/08/14 12:44
CRDT- 2023/08/14 07:13
PHST- 2023/08/14 12:44 [medline]
PHST- 2023/08/14 12:43 [pubmed]
PHST- 2023/08/14 07:13 [entrez]
AID - 10.1080/14712598.2023.2247972 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2023 Jul-Dec;23(8):653-657. doi: 
      10.1080/14712598.2023.2247972. Epub 2023 Aug 18.